Vice President, Global Drug Safety
ADC TherapeuticsHighlight
Summary
About the Role
About You
- MD required
- 7 years of clinical development experience including 4 years’ direct involvement in drug safety/pharmacovigilance activities
- In-depth knowledge of best drug safety/pharmacovigilance practices
- Expert knowledge in generation of periodic reports and safety input on Clinical Study Protocols, IBs, and Study Reports
- Proficient in drug safety regulations domestically and internationally including relevant GVP/GCP/ICH guidelines
- Technical knowledge of commercial drug safety databases, MedDRA and WHO Drug coding
- Experience with vendor oversight and management
- Demonstrates excellent organizational and management skills
- Effective communicator with strong verbal and written skills
- Clinical and analytical knowledge in relevant therapeutic areas
- Seen as a strong, influential leader and manager of employees
- Creates strong morale and spirit on his/her team
- Able to think creatively; develop and execute within a fast-paced environment
- 10% domestic travel
ADC Therapeutics is a commercial-stage global pioneer in the field of antibody drug conjugates (ADCs). Our goal is to be a leading ADC company that transforms the lives of those impacted by cancer. To achieve this, we are focused on unlocking the potential value of our robust ADC portfolio across two pillars of growth: hematology and solid tumors. We are a pioneer in the ADC field with specialized end-to-end capabilities unique to ADCs including a validated technology platform, a growing next-generation research & development toolbox and a proven track record that includes an approved and marketed product. We aim to expand our portfolio and accelerate the development of our pipeline through targeted investments and in collaboration with strategic partners. In this way, we plan to pursue multiple targets in parallel, enabling us to prioritize and ensure disciplined capital allocation strategy while advancing the most promising candidates in both hematology and solid tumors. Our CD19-directed ADC ZYNLONTA® (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. Founded in 2011, ADC Therapeutics is based in Lausanne, Switzerland, with operations in London and New Jersey. Our highly skilled global team is committed to confronting cancer with the full potential of our science and transforming the treatment paradigm for patients with cancer. For more information, please visit https://www.adctherapeutics.com/.